



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

June 17, 2021

Feng Tian  
Chairman, President and Chief Executive Officer  
Ambrx Biopharma Inc.  
10975 North Torrey Pines Road  
La Jolla, California 92037

**Re: Ambrx Biopharma Inc.**  
**Registration Statement on Form F-1**  
**Exhibit Nos. 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 & 10.10**  
**Filed May 28, 2021**  
**File No. 333-256639**

Dear Dr. Tian:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance